Indefinite-Lived Research and Development Assets
Gilead Sciences Indefinite-Lived Research and Development Assets remained flat by 0.0% to $2.30B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 20.4%, from $2.89B to $2.30B. Over 2 years (FY 2023 to FY 2025), Indefinite-Lived Research and Development Assets shows a downward trend with a -43.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
Detailed definition
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Peer comparison
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assetsHistorical Data
| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.07B | $4.64B | $4.64B | $2.89B | $2.89B | $2.89B | $2.70B | $2.70B | $2.30B | $2.30B |
| QoQ Change | — | -34.4% | +0.0% | -37.7% | +0.0% | +0.0% | -6.6% | +0.0% | -14.8% | +0.0% |
| YoY Change | — | — | — | — | -59.1% | -37.7% | -41.8% | -6.6% | -20.4% | -20.4% |
Indefinite-Lived Research and Development Assets at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's indefinite-lived research and development assets?
- Gilead Sciences (GILD) reported indefinite-lived research and development assets of $2.30B in Q1 2026.
- How has Gilead Sciences's indefinite-lived research and development assets changed year-over-year?
- Gilead Sciences's indefinite-lived research and development assets decreased by 20.4% year-over-year, from $2.89B to $2.30B.
- What is the long-term trend for Gilead Sciences's indefinite-lived research and development assets?
- Over 2 years (2023 to 2025), Gilead Sciences's indefinite-lived research and development assets has grown at a -43.0% compound annual growth rate (CAGR), from $7.07B to $2.30B.
- What does indefinite-lived research and development assets mean?
- The value of ongoing research projects acquired from other companies that are not yet ready for sale.